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Objective: To evaluate the performance of lung ultrasound to determine short-term 
outcomes of patients with COVID-19 admitted to the intensive care unit. Methods: This is 
a Prospective, observational study. Between July and November 2020, 59 patients were 
included and underwent at least two LUS assessments using LUS score (range 0-42) 
on day of admission, day 5th, and 10th of admission. Results: Age was 66.5±15 years, 
APACHE II was 8.3±3.9, 12 (20%) patients had malignancy, 46 (78%) patients had 
a non‑invasive ventilation/high‑flow nasal cannula and 38 (64%) patients required 
mechanical ventilation. The median stay in ICU was 12 days (IQR 8.5-20.5 days). ICU 
or hospital mortality was 54%. On admission, the LUS score was 20.8±6.1; on day 5th 
and day 10th of admission, scores were 27.6±5.5 and 29.4±5.3, respectively (P=0.007). 
As clinical condition deteriorated the LUS score increased, with a positive correlation of 
0.52, P <0.001. Patients with worse LUS on day 5th versus better score had a mortality 
of 76% versus 33% (OR 6.29, 95%CI 2.01-19.65, p. 0.003); a similar difference was 
observed on day 10. LUS score of 5th day of admission had an area under the curve 
of 0.80, best cut‑point of 27, sensitivity and specificity of 0.75 and 0.78 respectively. 
Conclusion: These findings position LUS as a simple and reproducible method to predict 
the course of COVID-19 patients.
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INTRODUCTION
The new coronavirus disease (COVID-19) can result in 
severe and even fatal respiratory diseases such as acute 
respiratory distress syndrome (ARDS).(1) Non-invasive 
diagnostic methods have gained ground in clinical practice, 
especially in critical and emergency medicine as rapid, 
reliable, and reproducible information at the patient’s 
bedside has contributed to the more accurate etiological 
diagnosis of acute pathology and a more targeted 
treatment.(2,3) In the context of the COVID-19 pandemic, 
ultrasound has become a useful tool in intensive care, 
with a POCUS (Point of Care Ultrasound) approach.(4)
Lung ultrasound (LUS) is available in countries with 
different levels of development of their healthcare 
systems and offers advantages compared to computed 
tomography (CT), which requires transferring patients 
outside intensive care units or chest radiography, which 
has shown limitations for the diagnosis and monitoring of 
pulmonary pathology in critical patients.(5) Several studies 
have shown that LUS can detect interstitial disease, 
subpleural consolidations, and respiratory distress of any 
aetiology, with sensitivity and specificity superior to chest 
radiography and comparable to CT.(6-8) Indeed, LUS has 
already been recommended in past viral pandemics(9) 
and growing evidence demonstrates its effectiveness in 
patients with COVID-19,(10) which allows identifying the 
degree of lung involvement, its course, and the possible 
association between the initial lung involvement and its 
prognosis.(11-15)
Our objective was to evaluate the performance of LUS 
through the lung ultrasound score (LUS score) to determine 
the severity of pneumonia and the short-term outcomes 
of patients with COVID-19 admitted to the intensive care 
unit. We hypothesize that the Lung Ultrasound Score 
(LUS) correlates with clinical evolution and predicts 
mortality in critically ill COVID-19 pneumonia patients.
METHODS
This is an observational, analytical, prospective, 
single-centre study performed at the Intensive Care 
Unit (ICU) of the Hospital Alemán in Buenos Aires, 
Argentina; a teaching hospital with a 30-bed ICU, 15 of 
these were purposed to COVID-19 care. The study 
was approved by the independent ethics committee of 
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Hospital Alemán. The informed consent of the patients 
or their representatives was obtained. The study was 
performed in compliance with Act 25.326/Habeas Data. 
We preserved the identity of the participants according 
to local and international standards and legislation.
We included all patients with a confirmed diagnosis 
of COVID-19 by polymerase chain reaction (PCR) 
techniques, admitted to the ICU with respiratory failure, 
between July 1, 2020, and October 31, 2020, and who 
had at least two LUS. LUS was performed at baseline 
(time of admission to ICU), on day fifth and day 10th of 
admission to ICU. We excluded patients under 18 years 
old, those whose reason for admission to the ICU was 
not respiratory failure despite a confirmed diagnosis of 
COVID-19, and those with advance directives and do 
not resuscitate orders. Patients with low supplemental 
oxygen requirements were admitted to the ICU they 
showed a rapid radiological progression, deterioration 
with tachypnoea, and/or poor ventilatory mechanics.
After obtaining informed consent and within 48 hours 
after admission to ICU, the first evaluation was 
performed using a Philips ultrasound machine, model 
CX 50, low-frequency convex transducer (2-6 MHz), 
with lung software (Philips Medical Systems, Bothell, 
WA, USA), at a pre-established depth of 11 to 14 cm. 
The LUS score was calculated according to methods 
described by Soldati et al. with a modification.(16) 
Instead of dividing the posterior areas into three 
regions, these were divided into two regions (upper and 
lower regions), and PLAPS point was added to lateral 
regions as pulmonary consolidation was observed. For 
this purpose, each hemithorax was divided into seven 
regions, right anterior between the clavicle upwards 
and the tenth intercostal space downwards, laterally 
between the right edge of the sternum and the anterior 
axillary line, and divided into upper and lower areas; 
right lateral between the axillary gap upwards and a 
line that continues from the tenth intercostal space 
downwards, between the anterior axillary lines and 
the posterior axillary line and divided into upper and 
lower; the posterior region was also divided into upper 
and lower, with lateral limits between the posterior 
axillary line and the spine and the superior region; and 
classified as follows: R1 (upper right anterior region) 
R2 (lower right anterior region), R3 (right axillary 
region), R4 (lower right lateral region), R5 (upper right 
posterior region), R6 (lower right posterior region), 
and R7 - PLAPS (posterior and/or lateral alveolar 
and/or pleural syndrome) (region between the union 
of the posterior axillary line and the intersection of 
the imaginary line that continues through the tenth 
intercostal space, requiring the visualization of the 
diaphragm for the correct exploration of the pleural 
fundus). In the same way and with equal limits, the left 
hemithorax was taken, naming each of the zones as 
L1 (upper left anterior region), L2 (lower left anterior 
region), L3 (left lateral region), L4 (lower left lateral 
region), L5 (upper left posterior region), L6 (lower left 
posterior region), and L7 – PLAPS. Figure 1 shows 
LUS regions.
Each area was assigned a value according to the 
following assessment from 0 to 3 points. A-lines: normal 
pleural line, normal reverberation artifacts of the pleural 
line accompanied by lung sliding, corresponding to 
normal lung aeration = 0 points. B-lines: hyperechoic 
lines vertical to the pleural line rising from it and 
reaching the end of the screen, erasing the A-lines 
or in concert with them in the case of pulmonary 
pathology associated with COVID-19, representing 
reverberant artifacts of interlobar or oedematous 
alveolar septa, were divided into B1 separate B-lines 
corresponding to moderate loss of lung aeration 
= 1 point. Three or more lines define B1. B2 coalescent 
B-lines corresponding to a severe loss of pulmonary 
Figure 1. Caption. Lung Ultrasound Score regions.
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aeration, which was = 2 points, and pulmonary 
consolidation which was = 3 points.(17) Thus, the LUS 
score could have a normal value of 0 and the worst 
value of 42. This evaluation was performed by three 
intensive care physicians trained in performing LUS, 
at the bedside of the patient with confirmed COVID-19 
using an ultrasound machine exclusively dedicated 
to these patients. Personal protective equipment was 
used for all studies and measurements were taken 
offline to reduce exposure time. The interobserver 
variability for LUS score measurement was determined 
by an independent expert operator who was blinded 
to the study.
At each assessment, we recorded the clinical 
condition measured by the level of ventilatory support: 
“mild” when the patient required a nasal O2 cannula; 
“moderate” when the patient required non-invasive 
ventilation/high-flow nasal cannula; “severe” when the 
patient required mechanical ventilation. In addition, 
the following parameters were measured: leukocytes, 
C-reactive protein, platelets, LDH, troponin-t, ferritin, 
and D-dimer. This evaluation was repeated on days 
fifth and 10th of ICU admission. Also, we recorded 
the number of days of ICU and hospital admission, 
ICU and hospital mortality, the total days of mechanical 
ventilation, and destination after hospital discharge 
(Home - Home Admission - 3rd level health centre).
For statistical analysis, continuous data were 
expressed as mean and standard deviation (SD), 
or as median and interquartile range [IQR 25-75], 
as appropriate. Normality analysis was performed 
using the Shapiro-Wilk test. Categorical data were 
expressed as absolute values and/or percentages. 
Student’s t-test or Mann Whitney’s U-test was used to 
comparing parametric and non-parametric continuous 
variables, respectively; and the Chi-square test and 
Fisher’s exact tests were used to compare categorical 
variables. The relationship between the variables was 
initially determined through univariate analysis. For the 
multiple regression analysis, we selected the variables 
that we considered relevant (principle of parsimony) 
and/or those that in the univariate analysis resulted 
in a value p<0.1. Those patients with missing data 
on the variables of importance were excluded from 
the analysis. The statistical analyses were performed 
with the software R version 3.3.3.
RESULTS
During the four months of the study, 249 patients 
were admitted to ICU, of which 78 (31%) patients 
were diagnosed with COVID-19. A total of 19 patients 
were excluded for the following reasons: eight lacked 
ultrasound evaluations, five were admitted because of 
non-respiratory causes, five had a long hospital stay 
before the diagnosis of COVID-19 and one patient had 
a do-not-resuscitate/do-not intubate order. Finally, 
59 patients were included in the final analysis. The mean 
age was 66.5±15 years and 43 (73%) of 59 patients 
were male. Severity at admission measured by APACHE 
II averaged 8.3±3.9 and Charlson’s comorbidity score 
showed a mean of 3.2±2. Twelve (20%) patients had 
malignancy and 9 (15%) patients were fragile (Clinical 
Frailty Scale >4). In 46 (78%) patients, a non-invasive 
ventilation/high-flow nasal cannula was used, during a 
median of 3.5 days (IQR 2-6 days), and in 38 (64%) 
patients, mechanical ventilation was required, during 
a median of 12 days (IQR 9.25-19.75 days). The 
median stay in ICU was 12 days (IQR 8.5-20.5 days) 
and the median stay in hospital was 20 days 
(IQR 13.5-28.5 days). Mortality in ICU and hospital 
was 54%. The demographic characteristics of the 
patients are summarized in Table 1.
The median time from the diagnosis of COVID-19 to 
the first LUS was 5 days (IQR 3.5-9 days). The total 
median LUS score at admission was 20.8±6.1; at day 5, 
it was 27.6±5.5 and at day 10, 29.4±5.3 (p=0.007). 
As clinical condition deteriorated (according to the 
requirement for mechanical ventilation support), the 
LUS score increased, with a positive correlation of 0.52, 
p <0.001. On day 10 (n=41), LUS scores were 19.1±3.4, 
23.3±4.5, 30.8±5.3 in the mild, moderate, and severe 
groups, respectively. When analysing the biochemical 
markers at the time of the first LUS evaluation, none of 
them showed a statistically significant association with 
the clinical condition, unlike the LUS score. The group 
of patients whose LUS score at day 5 was worse than 
baseline had a 76% mortality versus a 33% mortality 
in the group of patients whose LUS scores improved 
during the same period (OR 6.29, 95%CI 2.01-19.65, 
p=0.003). Table 2 shows ICU mortality according to 
changes observed with the LUS score.
This difference was also observed on day 10 of 
admission to ICU. In multivariate analysis, adjusted by 
age, APACHE II, and Charlson, the LUS score was an 
independent predictor of mortality (OR 1.32, 95%CI 
1.14 -1.60, p=0.001). In another regression model 
in which sex and body mass index were adjusted, 
the LUS score was also an independent predictor of 
mortality (OR 1.30, 95%CI 1.14-1.54, p<0.001). The 
sensitivity and specificity of the LUS score to predict 
patient mortality were evaluated. The LUS score at 
ICU admission showed an area under the curve (AUC) 
of 0.64, with 25 as the best cut-point, sensitivity of 
0.63, and a specificity of 0.59. And on the fifth day 
after admission, the LUS score presented an AUC of 
0.80, with the best cut-point of 27, sensitivity and 
specificity of 0.75 and 0.78, respectively (Table 3 and 
Figure 2). Figure 3 shows examples of LUS images 
of patients included in the study.
DISCUSSION
Our findings show that lung ultrasound score is a 
feasible and easy method to predict the clinical course 
of critically ill patients with COVID-19. When patients’ 
clinical condition deteriorated, the score significantly 
increased. Indeed, the LUS score was an independent 
predictor of mortality and when assessed on day 5 of 
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admission to ICU, the score presented an acceptable 
area under the curve.
The histopathologic features of COVID-19 pneumonia 
are characterized by alveolar damage, including alveolar 
oedema, while the inflammatory component is mild 
and patchy. Reparative processes with hyperplasia of 
pneumocytes and interstitial thickening may then occur; 
in advanced phases, there appear gravity-dependent 
consolidations similar to those of respiratory distress, 
as well as haemorrhagic necrosis, alveolar congestion, 
oedema, desquamation, and fibrosis.(18) Therefore, 
tools that can reliably assess lung involvement can 
also predict clinical deterioration. Our study suggests 
that the LUS score was useful to evaluate patients 
with COVID-19 and that, early after admission, could 
predict a higher risk of mortality.
The LUS score could define alterations that affect 
the relationship between tissue and air on the lung 
surface;(19) indeed, the higher score, the greater was the 
loss of pulmonary aeration. The median time between 
the diagnosis of COVID-19 and the first LUS evaluation 
was five days, and this may explain the difference 
between the first and the second LUS evaluation 
performance to predict unfavourable outcomes. In 
fact, the second evaluation was performed on average 
10 days after diagnosis, when COVID-19 presents 
an inflammatory peak, mainly due to the increase of 
proinflammatory cytokines.(20,21) It has been shown 
that patients with respiratory distress from COVID-19 
can retain near-normal lung compliance at the initial 
stages of the disease despite good oxygenation to 
later deteriorate or improve.(22,23)
Table 1. Demographic and clinical characteristics.
Characteristics Value in total patients (n = 59)
Age, mean±SD 66.5 ±15.0
Male, n (%) 43 (73)
APACHE II. mean±SD 8.3±3.9
Charlson Score. mean±SD 3.2±2.0
Cancer, n (%) 12 (20)
Fragile patients (CFS >4). n (%) 9 (15)
BMI, mean±SD 27.6±4.5
Support
Non-invasive ventilation/high-flow nasal cannula, n (%) 46 (78)
Days of the cannula, median (IQR) 3.5 (2-6)
Mechanical ventilation, n (%) 38 (64)
Days of MV. median (IQR) 12 (9.25-19.75)
ECMO, n (%) 1 (2)
Haemodialysis, n (%) 9 (15)
Neuromuscular blocking agents, n (%) 35 (59)
Days of neuromuscular blocking agents, median (IQR) 8 (5-10)
Days from diagnosis to LUS, median (IQR) 5 (3.5-9)
Length of ICU stay, days, median (IQR) 12 (8.5-20.5)
Length of hospital stay, days, median (IQR) 20 (13.5-28.5)
ICU mortality, n (%) 32 (54)
Hospital mortality, n (%) 32 (54)
Abbreviations: CFS = Clinical Frailty Scale; BMI = body mass index; APACHE = Acute Physiology and Chronic 
Health Evaluation; ECMO = extracorporeal membrane oxygenation; ICU = intensive care unit; SD = standard 
deviation; IQR = interquartile range.
Table 2. ICU mortality according to LUS score changes.
LUS score change n (%) ICU mortality (%) OR (CI 95%) P-value
LUS on 5th day of admission 0.003
Improved score 30 (51) 33
Deteriorated score 29 (49) 76 6.29 (2.01-19.65)
LUS on the 10th day of admission 0.023
Improved score 18 (44) 33
Deteriorated score 23 (56) 74 5.67 (1.47-21.89)
Improved or deteriorated compared to the previous assessment. LUS = Lung ultrasound score; ICU = intensive 
care unit; OR = odds ratio; CI = confidence interval.
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The LUS score showed an association to the clinical 
severity of patients with COVID-19 at the baseline 
assessment on the day of admission to ICU; however, 
it was on the fifth day of hospitalization that the 
score reached its best AUC to predict mortality. In 
a comparable study, this difference in the score was 
Table 3. Multivariate regression; mortality predicted by LUS.
Model OR (95%CI) p-value
Model 1 (adjusted by age, APACHE, Charlson) 1.32 (1.14-1.60) 0.001
Model 2 (adjusted by sex and BMI) 1.30 (1.14-1.54) < 0.001
ROC AUC Sensitivity Specificity PPV NPV
LUS at admission
LUS > 25 0.64 0.63 0.59 0.65 0.57
LUS on 5th day of admission
LUS > 27 0.80 0.75 0.78 0.80 0.72
AUC = area under the curve; ROC = receiver operating characteristic curve; PPV = positive predictive value; 
NPV = negative predictive value; LUS = Lung ultrasound score.
Figure 2. Sensitivity and specificity of the LUS score to predict patient mortality at the intensive care unit.
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already significant in the first LUS assessment.(24) 
Lichter et al.also showed that the LUS score could 
identify the appearance of pleural thickening and effusion, 
predicting clinical deterioration which translated to the 
need for mechanical ventilation and mortality.(24) In 
their study, an LUS score higher than 18 indicated a 
significantly lower survival.(24)
Our study was directed to the most critical group of 
patients with COVID-19 at our hospital; those patients 
who required hospitalization in ICU because of acute 
respiratory failure. As a result, our LUS score values 
were higher than those in previous publications, 
which included patients being admitted to emergency 
departments or general wards, in their initial stages 
of the disease.(13) In addition, we decided to include 
the lung lateral region to the axilla and to the PLAPS 
points, where pleural effusion and larger consolidations 
are usually observed. The pleura is not described in 
detail because although it was found to be altered 
(pleural disruption, pleural thickening), the transducer 
was intended for the assessment of type A, type B 
lung patterns, and subpleural consolidations and in the 
PLAPS points. bilateral pathological characteristics were 
found in 100% of our population, in concordance with 
other LUS studies in patients with COVID-19(18,20) and 
the most common findings were B lines and subpleural 
consolidations in posterior segments.
Our study has several limitations that should be taken 
into consideration when interpreting our results. It was 
performed in a single centre, with a small number of 
patients; some of them had been first admitted into 
the general ward before being transferred to ICU, 
overestimating the score cut point to predict poor clinical 
evolution and mortality. The use of a low-frequency, 
high-penetrance transducer could have missed a more 
accurate assessment of pleural line characteristics. 
Other limitations were that the onset of symptoms was 
not recorded, other infections were not assessed, and 
that not all potential confounders and effect modifiers 
were measured, such as lung oedema, as a result of 
limited resources during the pandemic.
Our findings must be interpreted with caution. 
Apart from the limitations listed above, it is critical 
that the implementation of lung ultrasound must be 
supervised by trained personnel. Our study contributes 
to the literature supporting the use of ultrasound lung 
evaluation as a simple method to predict the course 
of COVID-19 patients, their need for mechanical 
ventilation, and death. LUS is an easily available tool 
that could help clinicians plan the management of 
patients with COVID-19.
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Figure 3. LUS images of patients included in the study.
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